<![CDATA[The Billion Dollar Blindspot: Signal Not Noise]]>https://blog.billiondollarblindspot.com/s/signal-not-noisehttps://substackcdn.com/image/fetch/$s_!gFZE!,w_256,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2b97c421-4d4b-448e-8ae2-d844360f9d0e_500x500.pngThe Billion Dollar Blindspot: Signal Not Noisehttps://blog.billiondollarblindspot.com/s/signal-not-noiseSubstackThu, 09 Apr 2026 01:53:56 GMT<![CDATA[Gilead Just Paid $5 Billion for a European Biotech. The Indication Was Ovarian Cancer. That's Not a Coincidence.]]>https://blog.billiondollarblindspot.com/p/gilead-tubulis-european-biotech-exit-ovarian-cancer-capital-signalhttps://blog.billiondollarblindspot.com/p/gilead-tubulis-european-biotech-exit-ovarian-cancer-capital-signalWed, 08 Apr 2026 22:30:18 GMT📕Special note: My book The Billion Dollar Blindspot is available for pre-order on Amazon. It’s currently #3 on Amazon hot new releases in our category. Will you help me make it to #1?

Pre-order here

Gilead just paid $5 billion for a Munich biotech company. The deal was announced on Monday. The people who benefited from it were positioned years ago and in this article, I'm breaking down the signals they were watching so you know how to find the next one before the announcement.

Subscribe now

What happened

Gilead first partnered with Tubulis in December 2024 under an option and license agreement worth up to $465 million. Sixteen months later it didn’t just exercise the option. It bought the company.

What happened in between matters. Tubulis reported a 59% overall response rate in platinum-resistant ovarian cancer — an indication with no adequate standard of care and a patient population chronically underserved by both clinical investment and capital attention. The data moved Gilead from partner to acquirer.

And Gilead wasn’t the first major US strategic to take notice. BMS had also licensed Tubulis technology in 2023 for over $1 billion in milestones. Two of the world’s largest pharmaceutical companies had independently validated the same European platform.

Why it matters

US public R&D funding is under sustained structural pressure. Large pharma cannot rebuild deep-tech platform capability internally at the pace the competitive landscape demands. The efficient path (and Gilead has taken it three times this year alone) is acquisition of platform assets that have absorbed early-stage risk, demonstrated clinical signal, and retained scientific talent onshore. Tubulis is the European chapter of that strategy.

But here is the read that most coverage is missing this week.

When BMS licensed Tubulis technology in 2023, they validate the platform with that signal. When Gilead partnered sixteen months later, the auction had effectively started; it just hadn’t been announced yet.

Two major US strategics don’t independently license the same European platform without an acquisition becoming the logical endpoint. The people who understood that sequencing and were positioned in the cap table between those two events didn’t need Monday’s announcement. They were already there.

That pattern — strategic partnership as a structured private option, clinical data as the conversion trigger, acquisition as the public confirmation — is not unique to Tubulis. It is how large pharma has been systematically acquiring European deep-tech biotech for the better part of a decade.

It just rarely happens at this scale, with this speed, and with a women’s health indication (ovarian cancer) anchoring the lead program.

That last fact is the one worth sitting with. The women’s health indication didn’t discount this exit. It justified it and that distinction is about to matter for every European platform asset currently sitting at Series B or C with a gynecologic oncology program in the lead position.

What this signals for investors

The most important thing about the Tubulis exit isn’t the size.

Read more

]]><![CDATA[Organon Is Telling You Exactly What It Is and the Exit Math for Women's Health Has Changed]]>https://blog.billiondollarblindspot.com/p/organon-exit-landscape-womens-health-2026https://blog.billiondollarblindspot.com/p/organon-exit-landscape-womens-health-2026Sat, 04 Apr 2026 11:29:53 GMT📕Special note: My book The Billion Dollar Blindspot is available for pre-order on Amazon. It’s currently #3 on Amazon hot new releases in our category. Will you help me make it to #1?

Pre-order here

The most important acquirer in women’s health pharmaceuticals is subtly telling the market what it has become. Its not doing so through a press release but rather through a sequence of decisions made between October 2025 and March 2026 that, read together, paint a specific picture. Most investors in this space are reading them separately and that is the gap.

Organon, the MSD spin-out that holds Nexplanon, NuvaRing, and one of the largest women’s health commercial footprints in the world has spent the last five months selling assets, dropping R&D programs, licensing commercial-stage devices, running without a permanent CEO, and watching its share price sit roughly 63% below its three-year high. A non-binding acquisition approach from Sun Pharma surfaced in January, was publicly labelled speculative within days, and has since gone quiet.

OGN US. Source: Bloomberg

The Billion Dollar Blindspot is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

What happened

Between October 2025 and March 2026, Organon:

  • lost its founding CEO to a Nexplanon sales irregularity investigation

  • reported full-year 2025 revenue of $6.2B against $8.64B in debt

  • cut its quarterly dividend to $0.02

  • discontinued its entire internal R&D pipeline for endometriosis and PCOS (both acquired via Forendo in 2021)

  • divested its JADA postpartum hemorrhage system for $465M

  • and licensed in MIUDELLA, the first new hormone-free copper IUD in the US in 40 years for $27.5M upfront.

In addition, guidance for FY 2026 is flat and the permanent CEO search is ongoing.

Why it matters

What Organon’s portfolio moves reveal is a deliberate strategic retreat: from originating science in women’s conditions toward distributing and commercialising proven products.

That is a rational response to $8.64B in debt and a governance crisis. It is also a structural shift in what Organon is and what it can offer the ecosystem that has been building toward it as an acquirer.

The endometriosis and PCOS pipeline drops are worth sitting with. These are two of the highest-unmet-need, highest-diagnostic-delay conditions in women’s health. Organon acquired rights to drug candidates in both, and has now walked away from both. At the same time, it licensed a commercial-stage contraceptive device.

That sequencing tells you something precise about what Organon is becoming. The more important question for anyone building or backing companies in this space is what that becoming means for where exits go from here.

Read more

]]><![CDATA[The Menopause Drug Market Just Split in Two and the Capital Opportunity Is Bigger Than Either Drug]]>https://blog.billiondollarblindspot.com/p/signal-not-noise-menopause-drug-market-split-capital-opportunityhttps://blog.billiondollarblindspot.com/p/signal-not-noise-menopause-drug-market-split-capital-opportunitySun, 29 Mar 2026 23:16:54 GMT📕Special note: My book The Billion Dollar Blindspot is available for pre-order on Amazon. It’s currently #3 on Amazon hot new releases in our category. Will you help me make it to #1?

Pre-order here

Read more

]]><![CDATA[The Signals I’m Watching in Women’s Health as 2026 Approaches]]>https://blog.billiondollarblindspot.com/p/womens-health-investing-signals-2026https://blog.billiondollarblindspot.com/p/womens-health-investing-signals-2026Sun, 28 Dec 2025 14:05:26 GMT Read more

]]><![CDATA[Signal Not Noise: Clarity’s FDA Win, Progyny x Amazon, and the Rise of Hormone Health Infrastructure]]>https://blog.billiondollarblindspot.com/p/signal-not-noise-amazon-progyny-fda-clarity-aihttps://blog.billiondollarblindspot.com/p/signal-not-noise-amazon-progyny-fda-clarity-aiSat, 14 Jun 2025 21:48:44 GMTWelcome to Signal Not Noise. Your weekly roundup from FemmeHealth Ventures Alliance. We decode the week’s top headlines in women’s health innovation through a disciplined investor lens. New here? Tap the subscribe button to follow along each week inside the app.

Subscribe now

This newsletter is 100% free. But it takes hours each week to research, write, and produce a…

Read more

]]><![CDATA[Signal Not Noise: Flo’s Data Reckoning, Evvy’s Expansion & Toxic Tampons Wake Up the Market]]>https://blog.billiondollarblindspot.com/p/flo-evvy-lawsuit-tampon-safety-womens-health-investinghttps://blog.billiondollarblindspot.com/p/flo-evvy-lawsuit-tampon-safety-womens-health-investingFri, 06 Jun 2025 21:56:20 GMTFrom lawsuits to product launches, this week’s headlines reveal more than noise. They signal how women’s health is being redefined as a serious market. Here’s what investors should really be watching.

Read more

]]><![CDATA[Signal Not Noise: Hologic’s Bet, Hormona’s Raise & Insurance-Backed Longevity for Women]]>https://blog.billiondollarblindspot.com/p/womens-health-investing-hologic-ai-2025https://blog.billiondollarblindspot.com/p/womens-health-investing-hologic-ai-2025Sun, 01 Jun 2025 01:22:13 GMTThis week, from billion-dollar buyouts to stealth-stage AI, women’s health is evolving fast but capital is still favoring the familiar over the frontier.”

Read more

]]><![CDATA[Signal Not Noise: What Mattered in Women’s Health Investing (May 11–May 17)]]>https://blog.billiondollarblindspot.com/p/ai-infrastructure-womens-health-may-2025https://blog.billiondollarblindspot.com/p/ai-infrastructure-womens-health-may-2025Sat, 17 May 2025 15:11:02 GMTThis week, the signal wasn’t just what AI could do but what systems must do to contain it.

Read more

]]><![CDATA[Signal Not Noise: What Mattered in Women’s Health Investing (May 4–May 10)]]>https://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-in-368https://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-in-368Sat, 10 May 2025 10:06:00 GMTThis week’s signals reveal a new threshold: regulatory approvals, funding rounds, and product-market fits that move women's health innovation beyond pitch decks and into real-world delivery.

From the FDA greenlighting the first self-collected cervical cancer screening device, to FemTech markets attracting new capital with global traction, the contours of…

Read more

]]><![CDATA[Signal Not Noise: What Mattered in Women’s Health Investing (Apr 27–May 3)]]>https://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-in-b11https://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-in-b11Sat, 03 May 2025 18:25:01 GMTThis week’s signals tell a different kind of story: the capital stack for women’s health is quietly evolving through asset deals, institutional alliances, and science-driven care platforms.

From biotech acquisitions in ovarian aging to the institutional signaling power of the Milken Institute, this isn’t hype. It’s architecture. The scaffolding is going …

Read more

]]><![CDATA[Signal Not Noise: What Mattered in Women’s Health Investing (Apr 20–26)]]>https://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-in-c55https://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-in-c55Sat, 26 Apr 2025 09:53:36 GMTThis week’s signals tell a clear story: women’s health is expanding, not through headlines, but through steady shifts in capital, corporate strategy, and care models.

From autoimmune therapies to maternal mental health partnerships, the landscape is broadening. And for those paying close attention, the opportunity is growing wider, deeper, and harder to…

Read more

]]><![CDATA[Signal Not Noise: What Mattered in Women’s Health Investing (Apr 14–19)]]>https://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-in-45bhttps://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-in-45bSat, 19 Apr 2025 05:42:20 GMTWhat if the real signal this week wasn’t another funding headline but how we measure credibility? From regulatory risk to clinical validation, a new bar is emerging. Startups aren’t just expected to build, they are expected to prove. The women's health market is trading on more than promises. It’s asking for evidence.

Read more

]]><![CDATA[Signal Not Noise: What Mattered in Women’s Health Investing (Apr 7–14)]]>https://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-inhttps://blog.billiondollarblindspot.com/p/signal-not-noise-what-mattered-inMon, 14 Apr 2025 13:52:19 GMTWhat if the real headline this week wasn’t who invested but how the market is being redefined? From statehouse bills to creative capital structures, the signals point to a category gaining clarity, not just capital. Women’s health is no longer waiting for permission. It’s building momentum.

Read more

]]><![CDATA[Signal Not Noise: This Week in Women’s Health Investing (Mar 30–Apr 6)]]>https://blog.billiondollarblindspot.com/p/signal-not-noise-this-week-in-womenshttps://blog.billiondollarblindspot.com/p/signal-not-noise-this-week-in-womensMon, 07 Apr 2025 16:27:28 GMTThis week: macro validation, policy risks, AI in maternity care, and why Femtech needs its GLP-1 moment.

Read more

]]>